Abstract:The limitations of highly active anti-retroviral therapy have necessitated the development of alternative therapeutics for human immunodeficiency virus type-1 (HIV-1)-infected patients with dysfunctional dendritic cells (DCs) and CD4(+) T cell deficiency. We previously demonstrated that HIV-1 Gp120-specific T cell-based Gp120-Texo vaccine by using ConA-stimulated C57BL/6 (B6) mouse CD8(+) T(ConA-T) cells with uptake of pcDNA(Gp120)-transfected B6 mouse DC line DC2.4 (DC2.4(Gp120))-released exosomes (EXOGp120) was capable of stimulating DC and CD4(+) T cell-independent CD8(+) cytotoxic T lymphocyte (CTL) responses detected in wild-type B6 mice using non-specific PE-anti-CD44 and anti-IFN-gamma antibody staining by flow cytometry. To assess effectiveness of Gp120-Texo vaccine in transgenic (Tg) HLA-A2 mice mimicking the human situation, we constructed adenoviral vector AdV(Gp120) expressing HIV-1 GP120 by recombinant DNA technology, and generated Gp120-Texo vaccine by using Tg HLA-A2 mouse CD8(+) ConA-T cells with uptake of AdV(Gp120)-transfected HLA-A2 mouse bone marrow DC (DCGp120)-released EXOGp120. We then performed animal studies to assess Gp120-Texo-induced stimulation of Gp120-specific CTL responses and antitumor immunity in Tg HLA-A2 mice. We demonstrate that Gp120-Texo vaccine stimulates Gp120-specific CTL responses detected in Tg HLA-A2 mice using Gp120-specific PE-HLA-A2/Gp120 peptide (KLTPLCVTL) tetramer staining by flow cytometry. These Gp120-specific CTLs are capable of further differentiating into functional effectors with killing activity to Gp120 peptide-pulsed splenocytes in vivo. In addition, Gp120-Texo vaccine also induces Gp120-specific preventive, therapeutic (for 6 day tumor lung metastasis) and CD4(+) T cell-independent long-term immunity against B16 melanoma BL6-10(Gp120/A2Kb) expressing both Gp120 and A2Kb (alpha 1 and alpha 2 domains of HLA-A2 and alpha 3 domain of H-2K(b)) in Tg HLA-A2 mice. Taken together, the novel CD8(+) Gp120-Texo vaccine capable of stimulating efficient CD4(+) T cell-independent Gp120-specific CD8(+) CTL responses leading to therapeutic and long-term immunity in Tg HLA-A2 mice may represent a new immunotherapeutic vaccine for treatment of HIV-1 patients with CD4(+) T cell deficiency. (C) 2012 Elsevier Ltd. All rights reserved.

Novel Exosome-Targeted T-Cell-Based Vaccine Counteracts T-Cell Anergy and Converts Ctl Exhaustion in Chronic Infection Via Cd40l Signaling Through the Mtorc1 Pathway

CD40 Agonist Converting CTL Exhaustion Via the Activation of the Mtorc1 Pathway Enhances PD-1 Antagonist Action in Rescuing Exhausted CTLs in Chronic Infection.

The Tat Protein Enhances CTL Responses and Therapeutic Immunity of Gag-Specific Exosome-Targeted T Cell-Based Gag/Tat-Texo Vaccine in Transgenic HLA-A2 Mice

Novel Exosome-Targeted Cd4(+) T Cell Vaccine Counteracting Cd4(+)25(+) Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory Cd8(+) Ctl Responses

Killing HIV-infected Resting Central Memory CD4+ T Cells by Targeting Inhibitor of Apoptosis Proteins-Inhibited Autophagy

Transgenic 4-1Bbl-engineered Vaccine Stimulates Potent Gag-specific Therapeutic and Long-Term Immunity Via Increased Priming of CD44+CD62Lhigh IL-7R+ CTLs with Up- and Downregulation of Anti- and Pro-Apoptosis Genes

A Novel Therapeutic Vaccination Delays Cart-Resistant Hiv-1 Reservoir Rebound in Hiv-1 Infected Humanized Mice

A Novel T Cell-Based Vaccine Capable of Stimulating Long-Term Functional CTL Memory Against B16 Melanoma Via CD40L Signaling

GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses

Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.

HIV-1 Gag-specific exosome-targeted T cell-based vaccine stimulates effector CTL responses leading to therapeutic and long-term immunity against Gag/HLA-A2-expressing B16 melanoma in transgenic HLA-A2 mice

Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.

Restoring function in exhausted CD8 T cells during chronic viral infection

Dendritic Cells Recruit T Cell Exosomes Via Exosomal LFA-1 Leading to Inhibition of CD8+ CTL Responses Through Downregulation of Peptide/MHC Class I and Fas Ligand-Mediated Cytotoxicity

TLR3 Agonist and CD40-targeting Vaccination Induces Immune Responses and Reduces HIV-1 Reservoirs

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

mTOR signals regulate T cell exhaustion and T cell responses during PD-1 targeted immunotherapy in chronic viral infection.

Reprogramming of exhausted T cells following elimination of chronic antigen exposure

CD4 + T cell-released exosomes inhibit CD8 + cytotoxic T-lymphocyte responses and antitumor immunity

The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T Cells During Chronic Viral Infection

Enhanced Suppression of Polyclonal CD8+25+ Regulatory T Cells Via Exosomal Arming of Antigen-Specific Peptide/mhc Complexes.